Term ended no later than Jun 27, 2026 · Medium confidence
20-year base term ended Jun 27, 2026
Jun 27, 2006
Jun 27, 2026
Jun 30, 2009
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is on file with no resolved reference, so no cap is applied and none is guessed. All three maintenance fees were paid, so no fee lapse ended it. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 27, 2006, when application 11/475,252, the earliest non-provisional in its chain, was filed (this one was filed May 31, 2007) | Jun 27, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer on file (approved), reference document not resolved | no cap applied, and none guessed | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | no later than Jun 27, 2026 | Medium confidence |
Partial family
| US 7,241,805 | Term ended Jun 2026 | Jun 2026 |
| US 7,569,610 | Term ended Jun 2026 | Jun 2026 |
| US 7,563,823 | Term ended Jun 2026 | Jun 2026 |
| US 7,553,992 | this patent no later than Jun 2026 | no later than Jun 2026 |
| US 7,649,019 | Term ended no later than Jun 2026 | no later than Jun 2026 |
| US 8,932,628 | Term ended no later than Sep 2026 | no later than Sep 2026 |
| Application 11/762,368 | Abandoned not computed | not computed |
| US 7,569,611 | Term ended Jun 2026 | Jun 2026 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 12, 2025 Reel 71088, frame 61 | Valeant International Bermuda | Valeant Holdings Ireland | Merger |
| May 15, 2025 Reel 71124, frame 602 | Valeant Holdings Ireland | Valeant Holdings Ireland, Luxembourg Branch | Merger |
| May 15, 2025 Reel 71125, frame 884 | Valeant Pharmaceuticals Ireland Limited | Bausch Health Ireland Limited | Change of Name |
| May 15, 2025 Reel 71130, frame 894 | Valeant Holdings Ireland, Luxembourg Branch | Valeant Pharmaceuticals Luxembourg S.À R.L. | Assignment of Assignor's Interest |
| May 15, 2025 Reel 71291, frame 512 | Valeant Pharmaceuticals Luxembourg S.À R.L. | Valeant Pharmaceuticals Ireland | Assignment of Assignor's Interest |
| Nov 20, 2025 Reel 73637, frame 1 | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc.; Bausch & Lomb Incorporated; Bausch & Lomb Pharma Holdings Corp.; Commonwealth Laboratories, LLC; Dow Pharmaceutical Sciences, Inc.; Ecr Pharmaceuticals Co., Inc.; Laboratoire Chauvin S.A.S.; Medicis Pharmaceutical Corporation; Onpharma Inc.; Orapharma, Inc.; Precision Dermatology, Inc.; Salix Pharmaceuticals, Ltd.; Salix Pharmaceuticals, Inc.; Santarus, Inc.; Solta Medical, Inc.; Synergetics USA, Inc.; Technolas Perfect Vision GmbH; Valeant Canada LP; Valeant Pharmaceuticals International; Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals North America LLC; Wirra IP Pty Limited; Valeant Pharma Poland SP. Z O.O.; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 Reel 73637, frame 222 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Ireland Limited; Bausch Health Companies Inc.; Bausch Health, Canada Inc.; Technolas Perfect Vision GmbH; Valeant Pharmaceuticals Luxembourg S.A R.L.; Valeant Pharma Poland Spolka Z Organiczona Odpowiedzialnoscia; Valeant SP. Z.O.O. | Release of Security Interest |
| Nov 20, 2025 Reel 73654, frame 300 | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Companies Inc.; Bausch Health, Canada Inc.; Bausch Health Ireland Limited; Solta Medical Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Aton Pharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Incorporated | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch & Lomb Pharma Holdings Corp. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Commonwealth Laboratories, LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Dow Pharmaceutical Sciences, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Ecr Pharmaceuticals Co., Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Laboratoire Chauvin S.A.S. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Onpharma Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Orapharma, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Precision Dermatology, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Ltd. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Salix Pharmaceuticals, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Santarus, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Synergetics USA, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Technolas Perfect Vision GmbH | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Canada LP | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals International, Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals North America LLC | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Wirra IP Pty Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharma Poland SP. Z O.O. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Luxembourg S.A R.L. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharmaceuticals Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Ireland Limited | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health Companies Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Bausch Health, Canada Inc. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant Pharma Poland Spolka Z Organiczona Odpowiedzialnoscia | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Valeant SP. Z.O.O. | Release of Security Interest |
| Nov 20, 2025 reel/frame not recorded | The Bank of New York Mellon, as Notes Collateral Agent | Solta Medical Ireland Limited | Release of Security Interest |
| Nov 25, 2025 Reel 73715, frame 375 | Bausch Health Ireland Limited | Jpmorgan Chase Bank, N.a. | U.S. Patent Security Agreement |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer is on file (approved) and its reference document is not resolved. A disclaimer would cap the term earlier than Jun 27, 2026. We will not guess the cap.